Presentació dels Hospitals
Col·labora

Unitat de Recerca en Lípids i Arteriosclerosi (URLA) i Unitat de Medicina Vascular i Metabolisme (UVASMET)

MALALTIES METABÒLIQUES I NUTRICIÓ
NUTRICIÓ DIABETIS OBESITAT COLESTEROL
OBJECTIUS

La Unitat de Recerca en Lípids i Arteriosclerosi es va crear el 1985. Hi treballen 18 persones (5 clínics UVASMET). L’objectiu del grup és l’atenció assistencial i l’activitat docent i de recerca dels trastorns del metabolisme lipídic. És un grup de recerca consolidat per la Generalitat de Catalunya, forma part del CIBERDEM, de l’IISPV i de la URV. Les línies de recerca principals són: Hipercolesterolèmia Familiar; bases moleculars de la dislipèmia aterògena; genètica i epigenètica dels trastorns lipídics.

 

RESPONSABLES

  • Dr. Josep Ribalta Vives

  • Dr. Lluís Masana Marín

  • Presentació
  • Línies de recerca
  • Membres del grup
  • Publicacions
  • Projectes
  • Transferència
  • Difusió
  • Contacte

La Unitat de Medicina Vascular i Metabolisme (UVASMET) té com a objectiu el diagnòstic i tractament de les alteracions severes del metabolisme lipídic i la hipertensió arterial com a mesures preventives de les seves conseqüències patològiques, en primer terme les malalties cardiovasculars, que continuen sent la primera causa de mortalitat al nostre país, però també les malalties pancreàtiques, hepàtiques, renals, associades a les alteracions del metabolisme lipídic.

En què som experts i ens quins àmbits podem col·laborar?

  • Assaig clínics en pacients afectes de dislipèmies, risc cardiovascular i altres.
  • Estudis avançats del metabolisme lipídic, inclosa la 1H-RNM de lipoproteïnes (Liposcale- www.biosferteslab.com)
  • Aïllament de lipoproteïnes per ultracentrifugació.
  • Biomarcadors de malalties metabòliques i inflamatòries.
  • Estudis genètics i epigenètics
  • Estudis de miRNA
  • Tècniques bàsiques de laboratori.
  • Cultius cel·lulars
  • Tècniques de biologia molècula

La recerca s’organitza de forma coordinada entre ambdues Unitats: URLA-UVASMET
Director: Lluís Masana
Co-Director URLA: Josep Ribalta

La recerca de la URLA s’organitza en les següents línies, sota la responsabilitat d’un investigador principal (IP):

  • Hipercolesterolèmia Familiar.
    Responsables: Lluís Masana i Núria Plana.
  • Metabolisme lipoproteic, arteriosclerosi, diabetis.
    Responsables: Lluís Masana i   Josefa Girona.
  • Miocardiopatia diabètica
    Responsable: Ricardo Rodríguez
  • Vesícules extracel·lulars i malalties cardiovasculars i metabòliques
    Responsable: Neus Martínez-Micaelo
  • Característiques aterogèniques de les lipoproteïnes
    Responsable: Josep Ribalta
  • Genètica i epigenètica de les dislipèmies i risc vascular
    Responsable: Montse Guardiola
  • Dislipèmia, paret vascular i malalties reumatològiques
    Responsable: Joan Carles Vallvé
  • Metabolisme lipídic i càncer (col·laboració amb Oncologia)
    Responsable: Sandra Guaita (Grup de Recerca Oncològica)

    Año

    Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men.

    Zamora A, Ramos R, Comas M, García M, Martí R, Plana N, Alves L, Ponjoan A, Rodríguez C, Ibarretxe D, Roman I, Marrugat J, Elosua R, Martín A, Masana L. Sci Rep. 2023. 13. (1):p. 1492-1492.

    Triglyceride content increases while cholesterol content decreases in HDL and LDL plus IDL fractions following normal meals: The Copenhagen General Population Study of 25, 656 individuals. Atherosclerosis.

    Johansen MO, Moreno J, Balling M, Smith GD, Nordestgaard BG.  2023. 383. 117316. 98

    Serum branch-chained amino acids are increased in type 2 diabetes and associated with atherosclerotic cardiovascular disease.

    Moreno J, Llop D, Rodríguez R, Plana N, Amigó N, Rosales R, Esteban Y, Girona J, Masana L, Ibarretxe D.  Cardiovasc Diabetol. 2023. 22. (1):p. 249-249.

    Real life data: Follow-up assessment on Spanish gaucher disease patients treated with eliglustat. TRAZELGA project.

    Serrano I, De Frutos LL, Lahoz C, Delgado F, Fernández MÁ, Morales M, Calle MV, Ibarretxe D, Madinaveitia A, Albarracin A, Balanzat J, Correcher P, García LJ, Hernández JM, Labbadia F, Lopez JM, Lozano ML, Mora E, Noya MS, Ruíz MÁ, Del Mar Tormo M, Vitoria I, Arévalo I, Andrade M, Giraldo P. Orphanet J Rare Dis. 2023. 18. (1):p. 390-390.

    Pregnancy homocysteine and cobalamin status predict childhood metabolic health in the offspring.

    Rojas A, Solé P, Cavallé P, Ornosa G, Grifoll C, Ramos C, Fernández J, Masana L, Ballesteros M, Ueland PM, Murphy MM. Pediatr Res. 2023. 93. (3):p. 633-642.

    Plasma expression of carotid plaque presence-related MicroRNAs is associated with inflammation in patients with rheumatoid arthritis.

    Llop D, Paredes SR, Ibarretxe D, Taverner D, Plana N, Rosales R, Masana L, Vallvé JC. Int J Mol Sci. 2023. 24. (20):15347.

    PCSK9 inhibitors have apolipoprotein C-III-Related anti-inflammatory activity, assessed by 1H-NMR glycoprotein profile in subjects at high or very high cardiovascular risk.

    Rehues P, Girona J, Guardiola M, Plana N, Scicali R, Piro S, Muñiz O, Díaz JL, Recasens L, Pinyol M, Rosales R, Esteban Y, Amigó N, Masana L, Ibarretxe D, Ribalta J.  Int J Mol Sci. 2023. 24. (3):2319.

    PCSK9 inhibitors have anti-inflammatory activity assessed by 1H-NMR glycoprotein profile in subjects at high or very high cardiovascular risk. Atherosclerosis.

    Rehues P, Girona J, Guardiola M, Plana N, Scicali R, Piro S, Muñíz O, Díaz JL, Recasens L, Pinyol M, Rosales R, Esteban Y, Amigó N, Masana L, Ibarretxe D, Ribalta J. 2023. 379. p. 70-70.

    NMR-based metabolomic profiling identifies inflammation and muscle-related metabolites as redictors of incident type 2 diabetes mellitus beyond glucose: The Di@bet.es study.

    Ozcariz E, Guardiola M, Amigó N, Rojo G, Valdés S, Rehues P, Masana L, Ribalta J. Diabetes Res Clin Pract. 2023. 202. p. 110772-110772.

    Metabolic overlap between Alzheimer's disease and metabolic syndrome PVRL2 gene as a new modulator of diabetic dyslipidemia

    Guardiola M, Muntané G, Martínez I, Martorell L, Girona J, Ibarretxe D, Plana N, Bullido MJ, Vilella E, Ribalta J. . Int J Mol Sci. 2023. 24. (8):7415.

    Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.

    Blanco A, García J, Caixas A, Plana N, Rico MÁ, Bridges I, Dhalwani N, Gatell S, Ray K.  Clin Investig Arterioscler. 2023. 35. (6):p. 263-271.

    Lipoprotein profile assessed by 1H NMR, BMI and blood pressure are associated with vascular alterations in children with familial hypercholesterolaemia

    Llop D, Feliu A, Ibarretxe D, Escribano J, Plana N, Rodríguez C, Masana L, Vallvé JC. Nutr Metab Cardiovasc Dis. 2023. 33. (10):p. 2035-2043.

    Lipidomics of triglyceride-rich lipoproteins derived from hyperlipidemic patients on inflammation

    Moreno J, Llop D, Rodríguez R, Plana N, Amigó N, Rosales R, Esteban Y, Masana L, Ibarretxe D, Girona J.  Eur J Clin Invest. 2023. e14132.

    Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment.

    Masana L, Plana N, Andreychuk N, Ibarretxe D. Pharmacol Res. 2023. 190. p. 106738-106738.

    Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain. Atherosclerosis.

    Cosín J, Campuzano Ruiz R, Díaz Díaz JL, Escobar Cervantes C, Fernández MR, Gómez JJ, Mostaza JM, Pedro J, Plana N, Valdivielso P. 2023. 375:p. 38-44.

    Gradual increase in inflammation-linked glycoproteins and a proatherogenic lipoprotein profile in the early stages of psychosis as characterized by (1)H NMR blood analysis.

    Gallart X, Muntané G, Martorell L, Amigó N, Correig X, Ribalta J, Sánchez V, Labad X, Vilella E. J. Proteome Res. 2023. 22. (7):p. 2271-2280. 97

    Glycoprotein serum concentrations assessed by 1H-NMR are increased in patients with high blood pressure. Hypertension.

    Andreychuk N, Llop D, Moreno J, Girona J, Ibarretxe D, Rodríguez C, Plana N, Masana L.  2023. 80. (2):p. 460-469.

    Fatty acid binding proteins 3 and 4 predict both all-cause and cardiovascular mortality in subjects with chronic heart failure and type 2 diabetes mellitus.

    Rodríguez R, Granado M, de Oca A, Julian MT, Domingo M, Codina P, Santiago E, Cediel G, Julve J, Rossell J, Masana L, Mauricio D, Lupón J, Bayes A, Alonso N.  Antioxidants (Basel). 2023. 12. (3):645.

    Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies

    Narváez J, Estrada P, Llop D, Vidal P, Brugarolas E, Maymó P, Palacios J, Nolla JM.  Semin. Arthritis Rheum. 2023. 59152166.

    Economic burden associated with the treatment with a cardiovascular polypill in secondary prevention in Spain: Cost-effectiveness results of the NEPTUNO Study.

    Cordero A, González RD, Masana L, Fuster V, Castellano JM, Olivar J, Zsolt I, Sicras A, Juanatey JRG.  Clinicoecon Outcomes Res. 2023. 15. p. 559-571.

    Diagnosis of familial dysbetalipoproteinemia based on the lipid abnormalities driven by APOE2/E2 genotype.

    Bea AM, Cenarro A, Marco V, Laclaustra M, Martin C, Ibarretxe D, Pinto X, Arrobas T, Vinals C, Civeira F, Olmos S.  Clin Chem. 2023. 69. (2):p. 140-148.

    DDR1 and its ligand, collagen IV, are involved in in vitro oligodendrocyte maturation.

    Silva ME, Hernández M, Abasolo N, Espinoza C, Mansilla JB, Reyes CR, Aranda S, Esteban Y, Rodríguez R, Martorell L, Muntané G, Rivera FJ, Vilella E. Int J Mol Sci. 2023. 24. (2):1742.

    Associations between blood levels of trace elements and cardiovascular risk factors in patients with rheumatoid arthritis. Toxicol Lett

    Vera E, Vallvé JC, Linares MV, Belles M. 2023. 384. p. 149-150.

    Association between nordic and mediterranean diets with lipoprotein phenotype assessed by (1)HNMR in children with familial hypercholesterolemia. Atherosclerosis.

    Rodríguez C, Narveud I, Christensen JJ, Ibarretxe D, Andreychuk N, Girona J, Torvik K, Folkedal G, Bogsrud MP, Retterstøl K, Plana N, Masana L, Holven KB. 2023. 373. p. 38-45.

    Association between exposure to air pollution and blood lipids in the general population of Spain. Eur J Clin Invest.

    Valdés S, Doulatram V, Maldonado C, Garcia E, Garcia S, Oualla W, Garcia M, Garrido J, Gil V, Martin F, Calle A, Castaño L, Delgado E, Menéndez E, Franch J, Gaztambide S, Girbés J, Chaves F, Galán J, Aguilera G, Vallvé JC, Amigó N, Guardiola M, Ribalta J, Rojo G. 2023. e14101.

    Age exacerbates triglyceride-induced HDLC-lowering in women. Atherosclerosis.

    Guardiola M, Vallvé JC, Rehues P, Rojo G, Ribalta J. 2023. 379. p. 67-67.

    A panel of plasma microRNAs improves the assessment of surrogate markers of cardiovascular disease in rheumatoid arthritis patients. Rheumatology (Oxford).

    Llop D, Ibarretxe D, Plana N, Rosales R, Taverner D, Masana L, Vallvé JC, Paredes S. 2023. 62. (4):p. 1677-1686.

    2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: New treatments and clinical guidance.

    Cuchel M, Raal F, Hegele R, Al K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada M, Hudgins L, Kayikcioglu M, Masana L, Parhofer K, Roeters JE, Santos RD, Stroes E, Watts GF, Wiegman A, Stock JK, Tokgözoglu LS, Catapano AL, Ray KK. Eur Heart J. 2023. 44. (25):p. 2277-2291.

    Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol

    Masana L, Ibarretxe D, Plana N.
    Targets : Lipid-lowering combination therapy. Curr Cardiol Rep. 2020;22:66

    DOI: 10.1007/s11886-020-01326-w

    LDL Receptor Regulates the Reverse Transport of Macrophage-Derived Unesterified Cholesterol via Concerted Action of the HDL-LDL Axis: Insight from Mouse Models

    Cedo L, Metso J, Santos D, García-León A, Plana N, Sabate-Soler S, Rotllan N, Rivas-Urbina A, Mendez-Lara KA, Tondo M, Girona J, Julve J, Pallarès V, Benitez-Amado A, Llorente Cortes V, Pérez A, Gómez-Coronado D, Ruotsalainen AK, Levonen AL, Sanchez-Quesada JL, Masana L, Kovanen PT, Jauhiainen MS, Lee-Rueckert M, Blanco-Vaca F, Escola-Gil JC.   Circ Res. 2020.

    DOI: 10.1161/CIRCRESAHA.119.316424

    Human Serum/Plasma Glycoprotein Analysis by 1H-NMR, an Emerging Method of Inflammatory Assessment

    Fuertes-Martín R, Correig X, Vallvé JC, Amigó N. J Clin Med. 2020;9:354

    DOI: 10.3390/jcm9020354

    Precipitated sdLDL: An easy method to estimate LDL particle size

    Fernández-Cidón B, Candás-Estébanez B, Ribalta J, Rock E, Guardiola-Guionnet M, Amigó N, Padró-Miquel A, Alía-Ramos P, Pintó-Sala X. J Clin Lab Anal. 2020;e23282.

    DOI: 10.1002/jcla.23282

    Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study

    Malo AI, Rull A, Girona J, Domingo P, Fuertes-Martín R, Amigó N, Rodríguez-Borjabad C, Martínez-Micaelo N, Leal M, Peraire J, Correig X, Vidal F, Masana L. J Clin Med. 2020;9:1344

    DOI: 10.3390/jcm9051344

    Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

    Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators.  N Engl J Med. 2020;382:1520-1530.

    DOI: 10.1056/NEJMoa1913805

    Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry

    Luirink IK, Hutten BA, Greber-Platzer S, Kolovou GD, Dann EJ, de Ferranti SD, Taylan C, Bruckert E, Saheb S, Oh J, Driemeyer J, Farnier M, Pape L, Schmitt CP, Novoa FJ, Maeser M, Masana L, Shahrani A, Wiegman A, Groothoff JW. Atherosclerosis. 2020;299:24-31

    DOI: 10.1016/j.atherosclerosis.2020.01.031

    Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. SEC Working Group for the 2019 ESC/EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe

    Colaboradores: Leopoldo Pérez de Isla, Lluís Masana, Rosa Argüeso, Raquel Campuzano, Isabel Egocheaga, Carlos Escobar, Lorenzo Fácila, Pedro Mata López, Miriam Rossi, Carmen Rus Mansilla, José Antonio Alarcón Duque, Vicente Arrarte, Gonzalo Barón, Vivencio Barrios, Amelia Carro, Almudena Castro, Juan Cosin-Sales, Rosa Fernández Olmo, José Gámez Martínez, Ana Huelmos, Miriam Sandín, Adriana Saltijeral, Alfonso Valle, Fernando Arribas, Gemma Berga Congost, Héctor Bueno, Arturo Evangelista, Ignacio Ferreira-González, Manuel Jiménez Navarro, Francisco Marín, Leopoldo Pérez de Isla, Antonia Sambola, Rafael Vázquez, Ana Viana-Tejedor, Borja Ibáñez, Fernando Alfonso. Rev Esp Cardiol. 2020;73:348-353

    DOI: 10.1016/j.rec.2019.11.019

    Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU)

    Masana L, López Miranda J, Civeira F, Reinares L, Guijarro C, Plana N, Cuenca R, Sánchez D, Hernández JL, Andrés R, Blanco A, Villamayor S. Clin Investig Arterioscler. 2020.

    DOI: 10.1016/j.arteri.2020.02.003

    Plasma glucose, triglycerides, VLDL, leptin and resistin levels as potential biomarkers for myocardial fat in mice

    Rodríguez-Calvo R, Samino S, Guaita-Esteruelas S, Martínez-Micaelo N, Heras M, Girona J, Yanes O, Correig X, Masana L. Clin Investig Arterioscler. 2020;32:8-14.

    DOI: 10.1016/j.arteri.2019.05.001

    Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology

    Escorbar C, Anguita M, Arrarte V, Barrios V, Cequier Á, Cosín-Sales J, Egocheaga I, López de Sa E, Masana L, Pallarès V, Pérez de Isla L, Pintó X; Expert reviewers. Rev. Esp. Cardiol. 2020;73:161-167

    DOI: 10.1016/j.rec.2019.08.012

    Low-density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: A Consensus Statement From the European Atherosclerosis Society Consensus Panel

    Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Eur Heart J. 2020 Jun 21;41:2313-2330

    DOI: 10.1093/eurheartj/ehz962

    Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia

    Rodríguez-Borjabad C, Malo AI, Ibarretxe D, Girona J, Heras M, Ferré R, Feliu A, Salvadó M, Varela A, Amigó N, Masana L, Plana N, on behalf of the DECOPIN Group. Clin Investig Arterioscler. 2020;32:49-58

    DOI: 10.1016/j.arteri.2019.10.001

    Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype

    Ramos R, Masana L, Comas-Cufí M, Garcia-Gil M, Martí-Lluch R, Ponjoan A, Plana N, Alves-Cabratosa L, Marrugat J, Elosua R, Dégano IR, Gomez-Marcos MA, Zamora A. Atherosclerosis 2020; 292: 42-51

    DOI: 10.1016/j.atherosclerosis.2019.10.016

    Gelsolin: a new biomarker of disease activity in SLE patients associeated with HDL-c

    Parra S, Heras M, Herrero P, Amigó N, Garcés E, Girona J, Correig X, Canela N, Castro A. Rheumatology 2020; 59:650-661

    DOI: 10.1093/rheumatology/kez293

    Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease

    Pedro-Botet J, López-Miranda J, Badimón L, Civeira F, Guijarro C, Millán J, Mostaza JM, Pintó X, Valdivielso P, Masana L
    Am J Cardiovasc Drugs. 2020 Aug;20(4):325-332.

    DOI: 10.1007/s40256-019-00376-y

    Mendelian Randomization Study of Obesity and Cerebrovascular Disease

    Marini S, Merino J, Montgomery BE, Malik R, Sudlow CL, Dichgans M, Florez JC, Rosand J, Gill D, Anderson CD
    Ann Neurol. 2020 Apr;87(4):516-524.

    DOI: 10.1002/ana.25686

    Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection

    Martín-Campos JM, Ruiz-Nogales S, Ibarretxe D, Ortega E, Sánchez-Pujol E, Royuela-Juncadella M, Vila À, Guerrero C, Zamora A, Soler I Ferrer C, Arroyo JA, Carreras G, Martínez-Figueroa S, Roig R, Plana N, Blanco-Vaca F, Xarxa d’Unitats de Lípids I Arteriosclerosi Xula.
    Biomedicines. 2020 Sep 15;8(9):353.

    DOI: 10.3390/biomedicines8090353

    Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary ArteryDisease on Cardiometabolic Risk Factors

    Merino J, Jablonski KA, Mercader JM, Kahn SE, Chen L, Harden M, Delahanty LM,Araneta MRG, Walford GA, Jacobs SBR, Ibebuogu UN, Franks PW, Knowler WC, FlorezJC; Diabetes Prevention Program Research Group.
    Diabetes. 2020 Jan;69(1):112-120.

    DOI: 10.2337/db19-0097

    LDL Cholesterol and Dysglycemia: an Intriguing Physiological Relationship

    Merino J, Rotter JI.
    Diabetes. 2020 Oct;69(10):2058-2060.

    DOI: 10.2337/dbi20-0031

    Effect of statin therapy on SARS-CoV-2 infection-related

    Masana L, Correig E, Rodríguez-Borjabad C, Anoro E, Arroyo JA, Jericó C, Pedragosa A, Miret M, Näf S, Pardo A, Perea V, Pérez-Bernalte R, Plana N, Ramírez-Montesinos R, Royuela M, Soler C, Urquizu-Padilla M, Zamora A, Pedro-Botet J, Group OBOTSR.
    Eur Heart J Cardiovasc Pharmacother. 2020 Nov 2:pvaa128.

    DOI: 10.1093/ehjcvp/pvaa128

    Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic

    Rioja J, Ariza MJ, García-Casares N, Coca-Prieto I, Arrobas T, Muñiz-Grijalvo O, Mangas A, Ibarretxe D, Sánchez-Chaparro MÁ, Valdivielso P.
    Eur J Clin Invest. 2020 Dec;50(12):e13345.

    DOI: 10.1111/eci.13345

    EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study

    Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Hovingh GK, Jozwiak JJ, Jukema JW, Kiss RG, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR.
    2020 in press [Epub ahead of print]. Eur J Prev Cardiol.

    DOI: 10.1093/eurjpc/zwaa047

    Activation of nuclear factor-kappa B subunits c-Rel, p65 and p50 by plasma lipids and fatty acids across the menstrual cycle.

    Faustmann G, Tiran B, Trajanoski S, Obermayer-Pietsch B, Gruber HJ, Ribalta J, Roob JM, Winklhofer-Roob BM.
    Free Radic. Biol. Med. 2020 Nov 20;160:488-500.

    DOI: 10.1016/j.freeradbiomed.2020.08.012

    Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach

    Guijarro C, Civeira F, Masana L.
    JAMA Cardiol. 2020 Dec 1;5(12):1452-1453.

    DOI: 10.1001/jamacardio.2020.4114

    Human postprandial responses to food and potential for precision nutrition

    Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, Capdevila J, Hadjigeorgiou G, Davies R, Al Khatib H, Bonnett C, Ganesh S, Bakker E, Hart D, Mangino M, Merino J, Linenberg I, Wyatt P, Ordovas JM, Gardner CD, Delahanty LM, Chan AT, Segata N, Franks PW, Spector TD.
    Nat Med. 2020 Jun;26(6):964-973.

    DOI: 10.1038/s41591-020-0934-0

    Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes

    Climent E, Pérez-Calahorra S, Benaiges D, Pintó X, Suárez-Tembra M, Plana N, Sánchez-Hernández RM, Valdivielso P, Ascaso JF, Pedro-Botet J.
    Rev Esp Cardiol (Engl Ed). 2020 Sep;73(9):718-724. English, Spanish.

    DOI: 10.1016/j.rec.2019.09.001

    Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients

    Watts GF, Catapano AL, Masana L, Zambon A, Pirillo A, Tokgözoğlu L.
    Atheroscler Suppl. 2020 Dec;42:e30-e34.

    DOI: 10.1016/j.atherosclerosissup.2021.01.006

    Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project

    Landmesser U, Pirillo A, Farnier M, Jukema JW, Laufs U, Mach F, Masana L, Pedersen TR, Schiele F, Steg G, Tubaro M, Zaman A, Zamorano P, Catapano AL.
    Atheroscler Suppl. 2020 Dec;42:e49-e58.

    DOI: 10.1016/j.atherosclerosissup.2021.01.009

    Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms

    Rodríguez-Calvo R, Samino S, Girona J, Martínez-Micaelo N, Ràfols P, García-Altares M, Guaita-Esteruelas S, Junza A, Heras M, Yanes O, Correig X, Masana L.
    Biomolecules. 2020 Sep 3;10(9):1275.

    DOI: 10.3390/biom10091275

    Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®)

    Pintó X, Masana L, Civeira F, Real J, Ibarretxe D, Candas B, Puzo J, Díaz JL, Amigó N, Esteban M, Valdivielso P.
    Clin Investig Arterioscler. 2020 Sep-Oct;32(5):219-229. English, Spanish.

    DOI: 10.1016/j.arteri.2020.04.004

    Comparative efficacy betweeen atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence

    Pérez-Calahorra S, Laclaustra M, Marco-Benedi V, Pintó X, Sanchez-Hernandez RM, Plana N, Ortega E, Fuentes F, Civeira F. Lipids Health Dis. 2019; 18:216

    DOI: 10.1186/s12944-019-1153-x

    La asignación de factor impacto a Clínica e Investigación en Arteriosclerosis. Un objetivo cada vez más cercano

    Lahoz C, Ribalta J, Pintó X. Clin. Investig. Arterioscler. 2019; 31:261-262

    DOI: 10.1016/j.arteri.2019.10.005

    Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes

    Climent E, Pérez-Calahorra S, Benaiges D, Pintó X, Suárez-Tembra M, Plana N, Sánchez-Hernández RM, Valdivielso P, Ascaso JF, Pedro-Botet J. Rev Esp Cardiol. 2019; doi: 10.1016/j.rec.2019.09.001

    DOI: 10.1016/j.rec.2019.09.001

    The circulating GRP78/BiP is marker of metabolic diseases and atherosclerosis: bringing endoplasmatic reticulum stress into the clinical scenario

    Girona J, Rodríguez-Borjabad C, Ibarretxe D, Vallvé JC, Ferré R, Heras M, Rodríguez-Calvo R, Guaita-Esteruelas S, Martínez-Micaelo N, Plana N, Masana L. J Clin Med 2019; 8:1793

    DOI: 10.3390/jcm8111793

    Overall mortality and LDL cholesterol reduction in secondary prevention trials of cardiovascular disease

    Pedro-Botet J, López-Miranda J, Badimón L, Civeira F, Guijarro C, Millán J, Mostaza JM, Pintó X, Valdivieso P, Masana L; Expert group from the Spanish Arteriosclerosis Society. Am J Cardiovasc Drugs. 2019; doi: 10.1007/s40256-019-00376-y

    DOI: 10.1007/s40256-019-00376-y

    Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: Analysis of 5 years follow-up of real-world data from more than 1,5 milion patients

    Masana L, Zamora A, Plana N, Comas-Cufí M, Garcia-Gil M, Martí-Lluch R, Ponjoan A, Alves-Cabratosa L, Elosua R, Marrugat J, Dégano IR, Ramos R. J Clin Med 2019; 8:1080

    DOI: 10.3390/jcm8071080

    Update of therapeutic planning tables oriented towards obtaining therapeutic objectives

    Masana L, Plana N. Clin. Investig. Arterioscler. 2019; 31:271-277

    DOI: 10.1016/j.arteri.2019.04.005

    Effect of radiotherapy on the expression of cardiovascular disease-related miRNA-146a, -155, -221 and -222 in blood of women with breast cancer

    Esplugas R, Arenas M, Serra N, Bellés M, Bonet M, Gascón M, Vallvé JC, Linares V. PLoS One. 2019; 14:e0217443

    DOI: 10.1371/journal.pone.0217443

    HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk

    Girona J, Amigó N, Ibarretxe D, Plana N, Rodríguez-Borjabad C, Heras M, Ferré R, Gil M, Correig X, Masana L.  Int J Mol Sci. 2019; 20:3151

    DOI: 10.3390/ijms20133151

    MicroRNA differential expression shared between rheumatoid arthritis and acute myocardial infarction: an exploratory study

    Paredes S, Taverner D, Ferré R, Alegret JM, Masana L, Vallvé JC. Clin Exp Rheumatol. 2019; 37: 886-887

    PubMed: https://pubmed.ncbi.nlm.nih.gov/31172919/

    Niveles plasmáticos de glucosa, triglicéridos, VLDL, leptina y resistina como potenciales biomarcadores de la grasa miocárdica en ratones

    Rodríguez-Calvo R, Samino S, Guaita-Esteruelas S, Martínez-Micaelo N, Heras M, Girona J, Yanes O, Correig X, Masana L. Clin. Investig. Arterioscler. 2019; 96:12-21

    DOI: 10.1016/j.arteri.2019.05.001

    Indicaciones de los inhibidores de PCSK9 en la práctica clínica. Recomendaciones de la Sociedad española de Arteriosclerosis (SEA), 2019

    Ascaso JF, Civeira F, Guijarro C, López-Miranda J, Masana L, Mostaza JM, Pedro-Botet J, Pintó X, Valdivieso P.  Clin. Investig. Arterioscler. 2019; 31:128-139

    DOI: 10.1016/j.arteri.2019.04.002

    Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain

    Masana L, Ibarretxe D, Rodríguez-Borjabad C, Plana N, Valdivieso P, Pedro-Botet J, Civeira F, López-Miranda J, Guijarro C, Mostaza J, Pintó X; expert group from the Spanish Arteriosclerosis Society. Atherosclerosis 2019; 287:89-92

    DOI: 10.1016/j.atherosclerosis.2019.06.905

    Real-world outcomes with lomitapide use in paediatric patients with homozygous familial hypercholesterolemia

    Ben-Omar T, Masana L, Kolovou G, Ariceta G, Nóvoa FJ, Lund AM, Bogsrud MP, Araujo M, Hussein O, Ibarretxe D, Sánchez-Hernández RM, Santos RD. Adv Ther. 2019; 36:1786-1811

    DOI: 10.1007/s12325-019-00985-8

    Treating dyslipidemia: something more than giving statins

    Masana L. Clin. Investig. Arterioscler. 2019; 31:119-120

    DOI: 10.1016/j.arteri.2019.03.003

    Fatty acid binding protein 4 (FABP4) as a potencial biomarker reflecting myocardial lipid storage in type 2 diabetes

    Rodríguez-Calvo R, Girona J, Rodríguez M, Samino S, Barroso E, de Gonzalo-Calvo D, Guaita-Esteruelas S, Heras M, van der Meer RW, Lamb HJ, Yanes O, Correig X, Llorente-Cortés V, Vázquez-Carrera M, Masana L. Metabolism. 2019; 96:12-21

    DOI: 10.1016/j.metabol.2019.04.007

    Standards for global cardiovascular risk management arteriosclerosis

    Mostaza JM, Pintó X, Armario P, Masana L, Ascaso JF, Valdivieso P; en nombre de la Sociedad Española de Arteriosclerosis. Clin. Investig. Arterioscler. 2019; 31: 1-43

    DOI: 10.1016/j.arteri.2019.03.004

    Estimación del porcentaje de pacientes con enfermedad coronaria estable candidatos a recibir inhibidores de PCSK9. Respuesta

    Zamora A, Masana L, Plana N, Ramos R.  Rev. Esp. Cardiol. 2019; 72: 519-520

    DOI: 10.1016/j.recesp.2018.12.012
    Low-density lipoprotein net charge is a risk factor for atherosclerosis in lupus patients independent of lipid concentrations

    Rodríguez M, Guardiola M, Oliva I, Vallvé JC, Ferré R, Masana L, Parra S, Ribalta J, Castro A. Int J Rheum Dis. 2019;22:480-487

    DOI: 10.1111/1756-185X.13445

    Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives

    Rodríguez-Calvo R, Masana L. J Med Genet. 2019; 56:711-717

    DOI: 10.1136/jmedgenet-2018-105713

    Assessment of arterial stiffness variables in patients with rheumatoid arthritis: A mediation analysis

    Taverner D, Paredes S, Ferré R, Masana L, Castro A, Vallvé JC. Sci Rep. 2019; 9: 4543

    DOI: 10.1038/s41598-019-41069-5

    Palmitate decreases migration and proliferation and increases oxidative stress and inflammation in smooth muscle cells. Role of the Nrf2 signaling pathway

    Girona J, Rosales R, Saavedra P, Masana L, Vallvé JC. Am J Physiol Cell Physiol. 2019; 316: 888-897

    DOI: 10.1152/ajpcell.00293.2018

    Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia

    Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez-Tembra M, Civeira F, on behalf of the Dyslipemia Registry of Spanish Arteriosclerosis Society. Atherosclerosis 2019; 284:245-252

    DOI: 10.1016/j.atherosclerosis.2019.02.003

    Effect of radiation on the expression of CVD-related miRNAs, inflammation and endothelial dysfunction of HUVECs

    Esplugas R, Bellés M, Serra N, Arenas M, Hernández V, Vallvé JC, Linares V. Anticancer Res. 2019; 39: 771-780

    DOI: 10.21873/anticanres.13174

    Fluorescent labelling of membrane fatty acid transporter CD36 (SR-B2) in the extracellular loop

    Liu Y, Rodríguez-Calvo R, Wang S, Zhu X, Broers JLV, Glatz JFC, Luiken JJFP, Neumann D. PLoS One. 2019;4:e0210704

    DOI: 10.1371/journal.pone.0210704

    Criteria for referring patients to Spanish Atherosclerosis Society lipid units

    Sánchez-Chaparro MA, Pérez-Martínez P, Ibarretxe D, Suárez-Tembra M, Valdivieso P., en nombre del Grupo de Trabajo de las Unidades de Lípidos de la SEA. Clin. Investig. Arterioscler. 2019; 31: 26-30

    DOI: 10.1016/j.arteri.2018.04.005

    Extracellular FABP4 uptake by endothelial cells is depenent on cytokeratin 1 expression

    Martínez-Micaelo N, Rodríguez- Calvo R, Guaita-Esteruelas S, Heras M, Girona J, Masana L. Biochim Biophys Acta. 2019; 1864: 234-244

    DOI: 10.1016/j.bbalip.2018.11.011

  • Interplay between genetic determinants of glycemia, type 2 diabetes and cardiovascular disease in interaction with dietary and lifestyle factors.

    Marie Curie HORIZON 2020 CALL: H2020-MSCA-IF-2015,TOPIC:MSCA-IF-2015-GF, TYPE OF ACTION: MSCA-IF-GF, PROPOSAL NUMBER: 703787

    Investigador principal: Lluís Masana

    Entitat finançadora: European Commission

    Import concedit: 257.191,2€

    Número d’expedient: 703787-INTERPLAY

    Període d’execució: 2017-2020

  • Estudio epigenético para la mejora del diagnóstico genético de las hiperlipemias familiares.

    Investigadora principal: Montserrat Guardiola

    Entitat finançadora: Instituto de Salut Carlos III

    Inici-fi: 2020-2022

    Import concedit: 79.860,00€

    Número d’expedient: PI19/00832

  • Lipidómica por RMN de las lipoproteínas aterógenas no LDL en pacientes con dislipemia. Impacto sobre las complicacions vasculares y metabólicas.

    Investigadores principals: Josefa Girona; Daiana Ibarretxe.

    Entitat finançadora: Instituto de Salud Carlos III

    Inici-fi: 2019-2021

    Import concedit: 135.520€

    Número d’expedient: PI18/00515

  • Análisis lipídico avanzado para una major predicción del desarrollo de diabetes tipo 2 y eventos cardiovasculares: estudio transversal y longitudinal de la cohorte DI@BET.ES

    Investigador principal: Josep Ribalta

    Entitat finançadora: Instituto de Salud Carlos III

    Inici-fi: 2017-2019

    Import concedit: 88.935€

    Número d’expedient: PI16/00507

  • Chaperonas lipídicas circulantes y estrés del retículo endoplasmático: conexión clínica y patogénica entre obesidad, dislipemia aterógena y diabetes. PI15/00627

    Investigador principal: Lluís Masana

    Entitat financera: Instituto de Salud Carlos III

    Inici-fi: 2016-2019

    Import concedit: 183.315 €

  • Prevenir la malaltia coronària prematura a Catalunya augmentant el diagnòstic d’hipercolesterolèmia familiar.

    Investigador principal: Lluís Masana

    Entitat financera: Fundació La Marató de TV3

    Inici-fi: 2016-2019

    Import concedit: 291.835 €

  • Projectes de Recerca orientats a l’Atenció Primària en l’àmbit de la recerca i la innovació en salut. PERIS – SLT002/16/00145

    Investigador principal: Lluís Masana

    Entitat financera: Generalitat de Catalunya

    Inici-fi: 2017-2019

    Import concedit: 6.720,00 €

  • Projecte Europeu

    Interplay between genetic determinants of glycemia, type 2 diabetes and cardiovascular disease in interaction with dietary and lifestyle factors.

    Marie Curie HORIZON 2020 CALL: H2020-MSCA-IF-2015,TOPIC:MSCA-IF-2015-GF, TYPE OF ACTION: MSCA-IF-GF, PROPOSAL NUMBER: 703787

    Investigador principal: Lluís Masana

    Entitat finançadora: European Commission

    Import concedit: 257.191,2€

    Número d’expedient: 703787-INTERPLAY

    Període d’execució: 2017-2020

  • Title: Diabetis i malalties metabòliques associades (CIBER) CB07/08/0028.

    Funding entity: Instituto de Salud Carlos III

    Duration: 2008-2025

    Principal Investigator: Lluís Masana Marín

  • Title: 2017 SGR 00686 Suport a Grups de Recerca (SGR) URV – IISPV Finançament – Grup de recerca consolidat

    Funding entity: Agència de Gestió d’Ajuts Universitaris i de Recerca

    Duration: 2017-2020

    Principal Investigator: Lluís Masana Marín

  • PI21/01294: Estudio clínico e in vitro de las glicoformas de ApoC-III asociadas a lipoproteínas como biomarcadores de diabetes y su asociación con el riesgo cardiovascular en la cohorte prospectiva Di@betes.

    IP: Ribalta Vives, Josep.

    Team member: Girona Tell, Josefa; Masana Marín, Luis; Rehues Masip, Pere.

    Duration: 2022-2024.

    Funding entity: Instituto de Salud Carlos III.

  • PI19/00832: Estudio epigenético para la mejora del diagnóstico genético de las hiperlipemias familiares. [Proyectos de Investigación en Salud Instituto Carlos III].

    IP: Guardiola Guionnet, Montserrat.

    Investigadors: Plana Gil, Núria; Masana Marín, Luis.

    Duration: 2020-2023.

    Funding entity: Instituto de Salud Carlos III.

  • PI22/01974: Lipo y glicoproteinas por RMN en niños con hipercolesterolemia familiar.

    IP: Rodríguez Borjabad, Celia.

    Team member: Plana Gil, Núria; Masana Marín, Luis; Llop Paredes, Dídac.

    Duration: 2023-2025.

    Funding entity: Instituto de Salud Carlos III.

  • PI20/00443: Validation of plasma MicroRNAs (MIR-425-5p and MIR-451) as novel biomarkers of cardiovascular disease in patients affected with rheumatoid arthritis (LAMBDA study)

    IP: Vallvé Torrente, Joan Carles

    Duration: 2021-2024

    Funding entity: Instituto de Salud Carlos III

  • Inventors/es (per ordre de signatura): Mallol Parera, Roger; Amigó Grau, Núria; Correig Blanchar, Xavier; Masana Marín, Lluís; Rodríguez Martínez, Miguel Ángel; Heras Ibáñez, Mercedes; Plana Gil, Núria.

    Títol:  Methods for determining the lipid distribution between the core and the shell of a lipoprotein particle.

    Núm. de sol·licitud: EP13382477.1 País de prioritat: EPO Data de prioritat: 27/11/2013

    Entitat titular: Universitat Rovira i Virgili (URV) i Fundació Institut d’Investigació Sanitària Pere Virgili (IISPV).

    Empreses que l’exploten: BIOSFER TESLAB, SL

  • Inventors/es (per ordre de signatura):  Mallol Parera, Roger; Amigó Grau, Núria; Correig Blanchar, Xavier; Masana Marín, Lluís; Rodríguez Martínez, Miguel Ángel; Heras Ibáñez, Mercedes; Plana Gil, Núria;  Ribalta Vives, Josep.

    Títol: Method for the characterization of lipoproteins.

    Núm. de sol·licitud: EP12382478.9 País de prioritat: EPO Data de prioritat: 27/11/2013

    Entitat titular: Universitat Rovira i Virgili (URV) i Fundació Institut d’Investigació Sanitària Pere Virgili (IISPV)

    Empreses que l’exploten: BIOSFER TESLAB, SL

  • CONSTITUCIÓ SPIN-OFF

    Participació com a soci de l’EBT Spin-off BIOSFER TESLAB, SL, constituïda davant notari el 20/12/2013 amb número de protocol: 2105. Societat mercantil participada per les institucions: Universitat Rovira i Virgili i la Fundació Institut d’Investigació Sanitària Pere Virgili.

Membres De L’equip

  • Responsables de grup

    • Dr. Lluís Masana Marín
    • Dr. Josep Ribalta Vives

  • Equip de recerca

    • Núria Plana Gil
    • Joan Carles Vallvé Torrente
    • Josefa Girona Tell
    • Montserrat Guardiola Guionnet
    • Dra. Daiana Ibarretxe Guerediaga
    • Ricardo Rodríguez Calvo
    • Neus Martínez Micaelo
    • Iris Oliva Rodríguez
    • Yaiza Esteban Romero
    • Roser Rosales Ribas
    • Cèlia Rodríguez Borjabad
    • Juan Moreno Vedia
    • Pere Rehues Masip
    • Ana Irene Malo Cerisuelo

Altres grups de Malalties Metabòliques i Nutrició

Veure tots